Literature DB >> 22089661

Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset.

Angelina Cistaro1, Maria Consuelo Valentini, Adriano Chiò, Flavio Nobili, Andrea Calvo, Cristina Moglia, Anna Montuschi, Silvia Morbelli, Dario Salmaso, Piercarlo Fania, Giovanna Carrara, Marco Pagani.   

Abstract

PURPOSE: To identify the neurobiological traits of amyotrophic lateral sclerosis (ALS) and to elucidate functional differences between ALS of spinal and bulbar onset. We hypothesized that glucose metabolism distribution might vary between groups.
METHODS: The study groups comprised 32 patients with ALS of either bulbar (n = 13) or spinal (n = 19) onset and 22 subjects as controls. They were investigated by [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (FDG PET), comparing the patient groups with each other and with the controls by statistical parametric mapping.
RESULTS: Highly significant relative increases in glucose metabolism distribution were found in the group comprising all 32 ALS patients as compared with the controls in the bilateral amygdalae, midbrain, pons and cerebellum. Relative hypermetabolism was also found in patients with spinal onset as compared with the controls in the right midbrain. In patients with bulbar onset compared with the controls and with patients with spinal onset, large relatively hypometabolic areas were found in the bilateral frontal cortex, right insula, anterior cingulate, precuneus and inferior parietal lobe. Patients with spinal onset had significantly higher scores in a neuropsychological test assessing verbal fluency compared with patients with bulbar onset.
CONCLUSION: This large FDG PET investigation provided unprecedented evidence of relatively increased metabolism in the amygdalae, midbrain and pons in ALS patients as compared with control subjects, possibly due to local activation of astrocytes and microglia. Highly significant relative decreases in metabolism were found in large frontal and parietal regions in the bulbar onset patients as compared with the spinal onset patients and the controls, suggesting a differential metabolic and neuropsychological state between the two conditions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22089661     DOI: 10.1007/s00259-011-1979-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  42 in total

1.  Increased binding of 3H-L-deprenyl in spinal cords from patients with amyotrophic lateral sclerosis as demonstrated by autoradiography.

Authors:  S M Aquilonius; S S Jossan; J G Ekblom; H Askmark; P G Gillberg
Journal:  J Neural Transm Gen Sect       Date:  1992

Review 2.  Why glucose transport in the brain matters for PET.

Authors:  L Felipe Barros; Omar H Porras; Carla X Bittner
Journal:  Trends Neurosci       Date:  2005-03       Impact factor: 13.837

3.  The principled control of false positives in neuroimaging.

Authors:  Craig M Bennett; George L Wolford; Michael B Miller
Journal:  Soc Cogn Affect Neurosci       Date:  2009-12       Impact factor: 3.436

4.  Neuropsychological, electroencephalogram and brain computed tomography findings in motor neuron disease.

Authors:  R Gallassi; P Montagna; A Morreale; S Lorusso; P Tinuper; R Daidone; E Lugaresi
Journal:  Eur Neurol       Date:  1989       Impact factor: 1.710

5.  Cognitive impairment in amyotrophic lateral sclerosis and its relation to motor disabilities.

Authors:  Y Iwasaki; M Kinoshita; K Ikeda; K Takamiya; T Shiojima
Journal:  Acta Neurol Scand       Date:  1990-02       Impact factor: 3.209

6.  Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS).

Authors:  S Abrahams; P N Leigh; A Harvey; G N Vythelingum; D Grisé; L H Goldstein
Journal:  Neuropsychologia       Date:  2000       Impact factor: 3.139

7.  The relationship between abnormalities of cognitive function and cerebral activation in amyotrophic lateral sclerosis. A neuropsychological and positron emission tomography study.

Authors:  J J Kew; L H Goldstein; P N Leigh; S Abrahams; N Cosgrave; R E Passingham; R S Frackowiak; D J Brooks
Journal:  Brain       Date:  1993-12       Impact factor: 13.501

8.  Multiparametric assessment of acute and subacute ischemic neuronal damage: a small animal positron emission tomography study with rat photochemically induced thrombosis model.

Authors:  Dai Fukumoto; Teruyo Hosoya; Shingo Nishiyama; Norihiro Harada; Hiroshi Iwata; Shigeyuki Yamamoto; Hideo Tsukada
Journal:  Synapse       Date:  2011-03       Impact factor: 2.562

9.  Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis.

Authors:  Felix Geser; Nicholas J Brandmeir; Linda K Kwong; Maria Martinez-Lage; Lauren Elman; Leo McCluskey; Sharon X Xie; Virginia M-Y Lee; John Q Trojanowski
Journal:  Arch Neurol       Date:  2008-05

10.  Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis.

Authors:  Michael J Strong; Gloria M Grace; Morris Freedman; Cathy Lomen-Hoerth; Susan Woolley; Laura H Goldstein; Jennifer Murphy; Christen Shoesmith; Jeffery Rosenfeld; P Nigel Leigh; Lucie Bruijn; Paul Ince; Denise Figlewicz
Journal:  Amyotroph Lateral Scler       Date:  2009-06
View more
  57 in total

1.  Evolution of the neurochemical profiles in the G93A-SOD1 mouse model of amyotrophic lateral sclerosis.

Authors:  Hongxia Lei; Elisabeth Dirren; Carole Poitry-Yamate; Bernard L Schneider; Rolf Gruetter; Patrick Aebischer
Journal:  J Cereb Blood Flow Metab       Date:  2018-02-05       Impact factor: 6.200

2.  Prediagnostic body size and risk of amyotrophic lateral sclerosis death in 10 studies.

Authors:  Éilis J O'Reilly; Molin Wang; Hans-Olov Adami; Alvaro Alonso; Leslie Bernstein; Piet van den Brandt; Julie Buring; Sarah Daugherty; Dennis Deapen; D Michal Freedman; Dallas R English; Graham G Giles; Niclas Håkansson; Tobias Kurth; Catherine Schairer; Elisabete Weiderpass; Alicja Wolk; Stephanie A Smith-Warner
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2018-04-16       Impact factor: 4.092

Review 3.  Positron emission tomography in amyotrophic lateral sclerosis: Towards targeting of molecular pathological hallmarks.

Authors:  Stefanie M A Willekens; Donatienne Van Weehaeghe; Philip Van Damme; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-08       Impact factor: 9.236

Review 4.  Neuroimaging in genetic frontotemporal dementia and amyotrophic lateral sclerosis.

Authors:  Suvi Häkkinen; Stephanie A Chu; Suzee E Lee
Journal:  Neurobiol Dis       Date:  2020-09-02       Impact factor: 5.996

5.  Altered brain perfusion patterns in wakefulness and slow-wave sleep in sleepwalkers.

Authors:  Marie-Ève Desjardins; Andrée-Ann Baril; Jean-Paul Soucy; Thien Thanh Dang-Vu; Alex Desautels; Dominique Petit; Jacques Montplaisir; Antonio Zadra
Journal:  Sleep       Date:  2018-05-01       Impact factor: 5.849

6.  Comorbidity of dementia with amyotrophic lateral sclerosis (ALS): insights from a large multicenter Italian cohort.

Authors:  Francesca Trojsi; Mattia Siciliano; Cinzia Femiano; Gabriella Santangelo; Christian Lunetta; Andrea Calvo; Cristina Moglia; Kalliopi Marinou; Nicola Ticozzi; Gianluca Drago Ferrante; Carlo Scialò; Gianni Sorarù; Amelia Conte; Yuri M Falzone; Rosanna Tortelli; Massimo Russo; Valeria Ada Sansone; Adriano Chiò; Gabriele Mora; Barbara Poletti; Paolo Volanti; Claudia Caponnetto; Giorgia Querin; Mario Sabatelli; Nilo Riva; Giancarlo Logroscino; Sonia Messina; Antonio Fasano; Maria Rosaria Monsurrò; Gioacchino Tedeschi; Jessica Mandrioli
Journal:  J Neurol       Date:  2017-09-15       Impact factor: 4.849

7.  Combined brain and spinal FDG PET allows differentiation between ALS and ALS mimics.

Authors:  Donatienne Van Weehaeghe; Martijn Devrome; Michel Koole; Koen Van Laere; Georg Schramm; Joke De Vocht; Wies Deckers; Kristof Baete; Philip Van Damme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-04-20       Impact factor: 9.236

8.  Testing the diagnostic accuracy of [18F]FDG-PET in discriminating spinal- and bulbar-onset amyotrophic lateral sclerosis.

Authors:  Arianna Sala; Leonardo Iaccarino; Piercarlo Fania; Emilia G Vanoli; Federico Fallanca; Caterina Pagnini; Chiara Cerami; Andrea Calvo; Antonio Canosa; Marco Pagani; Adriano Chiò; Angelina Cistaro; Daniela Perani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-07       Impact factor: 9.236

9.  Neuronal glucose metabolism is impaired while astrocytic TCA cycling is unaffected at symptomatic stages in the hSOD1G93A mouse model of amyotrophic lateral sclerosis.

Authors:  Tesfaye W Tefera; Karin Borges
Journal:  J Cereb Blood Flow Metab       Date:  2018-03-19       Impact factor: 6.200

10.  Central white matter degeneration in bulbar- and limb-onset amyotrophic lateral sclerosis.

Authors:  Arturo Cardenas-Blanco; Judith Machts; Julio Acosta-Cabronero; Joern Kaufmann; Susanne Abdulla; Katja Kollewe; Susanne Petri; Hans-Jochen Heinze; Reinhard Dengler; Stefan Vielhaber; Peter J Nestor
Journal:  J Neurol       Date:  2014-07-25       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.